TRCT
ANTX icon

Tower Research Capital (TRC)’s AN2 Therapeutics ANTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.96K Sell
574
-1,466
-72% -$3.03K ﹤0.01% 4569
2025
Q4 		$2.33K Sell
2,040
-88
-4% -$103 ﹤0.01% 4552
2025
Q3 		$2.7K Sell
2,128
-3,185
-60% -$3.64K ﹤0.01% 4594
2025
Q2 		$5.63K Buy
5,313
+3,231
+155% +$3.85K ﹤0.01% 4166
2025
Q1 		$2.83K Buy
2,082
+619
+42% +$779 ﹤0.01% 4499
2024
Q4 		$2.02K Sell
1,463
-2,793
-66% -$3.39K ﹤0.01% 4924
2024
Q3 		$4.55K Sell
4,256
-1,150
-21% -$2K ﹤0.01% 4503
2024
Q2 		$11.6K Buy
5,406
+4,293
+386% +$10.2K ﹤0.01% 4071
2024
Q1 		$3.62K Buy
1,113
+1,050
+1,667% +$11.4K ﹤0.01% 4827
2023
Q4 		$1.29K Sell
63
-2,982
-98% -$49.9K ﹤0.01% 5404
2023
Q3 		$49K Buy
+3,045
New +$34.5K ﹤0.01% 2565
2023
Q2 		– Sell
-2,797
Closed -$28K – 6023
2023
Q1 		$28K Buy
2,797
+1,941
+227% +$21.6K ﹤0.01% 3056
2022
Q4 		$8K Sell
856
-423
-33% -$5.66K ﹤0.01% 4361
2022
Q3 		$22K Sell
1,279
-3,083
-71% -$35.9K ﹤0.01% 3849
2022
Q2 		$34K Buy
4,362
+3,709
+568% +$49.1K ﹤0.01% 3237
2022
Q1 		$10K Buy
+653
New +$9.91K ﹤0.01% 4273

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Tower Research Capital (TRC)'s ANTX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its AN2 Therapeutics (ANTX) stake by 72% in Q1 2026, selling an estimated $3.03K and leaving 574 shares worth $1.96K. The position accounts for ﹤0.01% of the portfolio, ranked #4569.

Tower Research Capital (TRC) first reported a position in ANTX in Q1 2022 and has held it in 16 quarters since. The position peaked at $49K in Q3 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Tower Research Capital (TRC) held 574 shares of AN2 Therapeutics worth $1.96K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,466 AN2 Therapeutics shares in Q1 2026, an estimated $3.03K.
  • AN2 Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4569 holding.
  • Tower Research Capital (TRC) first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • Tower Research Capital (TRC)'s AN2 Therapeutics position peaked at $49K in Q3 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.